Tarsus Pharmaceuticals, Inc. (TARS) stock
TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$78.20−0.48 (-0.61%)
Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%
Tarsus Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Tarsus Pharmaceuticals's total assets was $611.14M at Jun 30, 2026. For fiscal 2025 it was $562.16M, up 49.1% from the year before. The highest annual figure on record is $562.16M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $562.16M | +49.1% |
| FY2024 | Dec 31, 2024 | $376.99M | +42.0% |
| FY2023 | Dec 31, 2023 | $265.49M | +16.5% |
| FY2022 | Dec 31, 2022 | $227.86M | +27.4% |
| FY2021 | Dec 31, 2021 | $178.91M | +4.0% |
| FY2020 | Dec 31, 2020 | $171.97M | +194.9% |
| FY2019 | Dec 31, 2019 | $58.32M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $611.14M | +23.5% |
| Q1 FY2026 | Mar 31, 2026 | $581.14M | +16.1% |
| Q4 FY2025 | Dec 31, 2025 | $562.16M | +49.1% |
| Q3 FY2025 | Sep 30, 2025 | $534.56M | +42.1% |
| Q2 FY2025 | Jun 30, 2025 | $494.99M | +31.4% |
| Q1 FY2025 | Mar 31, 2025 | $500.75M | +43.4% |
| Q4 FY2024 | Dec 31, 2024 | $376.99M | +42.0% |
| Q3 FY2024 | Sep 30, 2024 | $376.30M | +40.2% |
| Q2 FY2024 | Jun 30, 2024 | $376.84M | +99.5% |
| Q1 FY2024 | Mar 31, 2024 | $349.28M | +65.4% |
| Q4 FY2023 | Dec 31, 2023 | $265.49M | +16.5% |
| Q3 FY2023 | Sep 30, 2023 | $268.33M | +13.5% |
| Q2 FY2023 | Jun 30, 2023 | $188.93M | -25.3% |
| Q1 FY2023 | Mar 31, 2023 | $211.21M | +16.4% |
| Q4 FY2022 | Dec 31, 2022 | $227.86M | +27.4% |
| Q3 FY2022 | Sep 30, 2022 | $236.47M | +24.2% |
| Q2 FY2022 | Jun 30, 2022 | $252.83M | +24.3% |
| Q1 FY2022 | Mar 31, 2022 | $181.48M | -6.4% |
| Q4 FY2021 | Dec 31, 2021 | $178.91M | +4.0% |
| Q3 FY2021 | Sep 30, 2021 | $190.41M | +106.6% |
| Q2 FY2021 | Jun 30, 2021 | $203.45M | +248.9% |
| Q1 FY2021 | Mar 31, 2021 | $193.95M | – |
| Q4 FY2020 | Dec 31, 2020 | $171.97M | – |
| Q3 FY2020 | Sep 30, 2020 | $92.19M | – |
| Q4 FY2019 | Dec 31, 2019 | $58.32M | – |
See a number that looks wrong?